Results of two recently released surveys show that symptoms of urinaryincontinence are prevalent in the U.S. population, and that incontinencesufferers are confused about the significance of the condition and oftendo not seek treatment.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.